Table 1.
Baseline characteristics
| Healthy controls (n = 17) | FTR (n = 22) | PCPH (n = 20) | P-value | |
|---|---|---|---|---|
| Age, years | 49 ± 13 | 78 ± 5† | 59 ± 17–†‡ | < 0.001 |
| Male Sex | 12 (71%) | 11 (50%) | 5 (25%)†‡ | 0.021 |
| BMI, kg/m2 | 24 ± 2 | 28 ± 5† | 26 ± 5 | 0.013 |
| NYHA/WHO-class I/II/III, n | – | 1/10/11 | 3/14/3 | 0.046 |
| Comorbidities | ||||
| Hypertension | – | 13 (59%) | 4 (20%) | 0.010 |
| Dyslipidemia | – | 7 (32%) | 3 (15%) | 0.201 |
| Diabetes Mellitus | – | 4 (18%) | 0 | 0.063 |
| Ischemic Heart Disease | – | 2 (9%) | 0 (0%) | 0.167 |
|
CKD (eGFR < 60 mL/min/1.73 m2) |
– | 8 (36%) | 6 (30%) | 0.662 |
| Medication | ||||
| ACEi or ARB | – | 10 (45%) | 3 (15%) | 0.033 |
| Betablockers | – | 12 (55%) | 0 (0%) | < 0.001 |
| Loop Diuretics | – | 17 (77%) | 9 (45%) | 0.031 |
| Mineralocorticoid receptor antagonist | – | 7 (32%) | 1 (5%) | 0.027 |
| Oral Anticoagulation | – | 21 (95%) | 13 (65%) | 0.012 |
| Calcium channel blockers | – | 8 (38%) | 1 (6%) | 0.020 |
| Laboratory data | ||||
| NT-proBNP, pmol/L | 37 (34, 96) | 1245 (817, 1849) † | 466 (132, 635) †‡ | < 0.001 |
| eGFR, mL/min/1.73 m2 | 92 ± 11 | 68 ± 20† | 79 ± 28 | 0.006 |
| Hemoglobin, mmol/L | 9.0 ± 0.9 | 8.4 ± 0.9 | 9.0 ± 0.9 | 0.063 |
Values are n (%), mean ± SD or median (interquartile range)
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FTR functional tricuspid regurgitation, NT-proBNP N-terminal pro brain-natriuretic-peptide, NYHA New York Heart Association, PCPH precapillary pulmonary hypertension, WHO World Health Organization
†Significantly different versus controls
†‡Significantly different versus FTR